Vaccine compositions against dengue virus diseases

A composition for use according to any preceding claim, wherein said human subject is dengue immune.

A composition for use according to any preceding claim, wherein said subject is aged between 2 and 60 years old.

A composition for use according to any preceding claim, wherein said subject is aged between 6 and 60 years old.

A composition for use according to any preceding claim, wherein said subject is at least 9 years of age.

A composition for use according to any preceding claim, wherein said subject is at least 12 years of age.

A composition for use according to any preceding claim, wherein said subject is aged between 9 and 60 years old.

A composition for use according to any preceding claim, wherein said subject is aged between 12 and 60 years old.

A composition for use according to any preceding claim, wherein said subject is aged between 9 and 16 years old.

A composition for use according to any preceding claim, wherein said composition comprises a dengue antigen of each of serotypes 1 to 4 which are each independently selected from the group consisting of:

• (a) a live attenuated dengue virus and (b) a live attenuated chimeric dengue virus.

A composition for use according to any preceding claim, wherein said composition comprises a dengue antigen of each of serotypes 1 to 4 and wherein said dengue antigens of serotypes 1, 3 and 4 are each a live attenuated chimeric dengue virus and said dengue antigen of serotype 2 is selected from the group consisting of a live attenuated dengue virus and a live attenuated chimeric dengue virus.

A composition for use according to any preceding claim, wherein said composition comprises a dengue antigen of each of serotypes 1 to 4 and wherein each of said dengue antigens is a live attenuated chimeric dengue virus.

A composition for use according to any preceding claim, wherein said live attenuated chimeric dengue virus comprises one or more proteins from a dengue virus and one or more proteins from a different flavivirus.

A composition for use according to any preceding claim, wherein the live attenuated chimeric dengue virus comprises a yellow fever virus genome whose prM-E sequence has been substituted with the prM-E sequence of a dengue virus.

A composition for use according to any preceding claim, wherein said subject is yellow fever immune.

A composition for use according to any preceding claim, wherein said subject resides in a dengue endemic area.

A composition for use according to any preceding claim, wherein said method comprises administering said composition in three or more doses.

A composition for use according to any preceding claim, wherein said dengue disease caused by a dengue virus of serotype 2 is dengue disease caused by a dengue virus of serotype 2 having an American, Asian/American, or a Cosmopolitan genotype.

A composition for use according to any preceding claim, wherein said composition further comprises a pharmaceutically acceptable carrier or excipient.

A composition for use in a method of protecting according to any preceding claim, wherein said method of protecting results in a statistically significant reduction in the incidence or likelihood, e.g. the prevention of, repeated symptomatic virologically-confirmed dengue cases due to any serotype, defined as ≧2 episodes of dengue due to different serotypes occurring more than 14 days apart.